Siefker-Radtke AO, Millikan RE, Tu S, et al. Phase III trial of fluorouracil, interferon alfa-2b, and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in metastatic or unresectable urothelial cancer. J Clin Oncol 2002;20:1361–1367.

• PubMed
Siefker-Radtke AO, Millikan RE, Tu S, Phase III trial of fluorouracil, interferon alfa-2b, and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in metastatic or unresectable urothelial cancer. J Clin Oncol 2002;20:1361–1367.)| false
• Search Google Scholar
• Export Citation

Bellmunt J, de Wit R, Vaughn DJ, et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med 2017;376:1015–1026.

• PubMed
Bellmunt J, de Wit R, Vaughn DJ, Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med 2017;376:1015–1026.28212060)| false
• Search Google Scholar
• Export Citation

Jiang Q, Fu Q, Chang Y, et al. CD19+ tumor-infiltrating B-cells prime CD4+ T-cell immunity and predict platinum-based chemotherapy efficacy in muscle-invasive bladder cancer. Cancer Immunol Immunother 2019;68:45–56.

• PubMed
Jiang Q, Fu Q, Chang Y, CD19+ tumor-infiltrating B-cells prime CD4+ T-cell immunity and predict platinum-based chemotherapy efficacy in muscle-invasive bladder cancer. Cancer Immunol Immunother 2019;68:45–56.30259082)| false
• Search Google Scholar
• Export Citation

Shin J, Chung J, Kim SH, et al. Effect of platinum-based chemotherapy on PD-L1 expression on tumor cells in non-small cell lung cancer. Cancer Res Treat 2019;51:1086–1097.

• PubMed
Shin J, Chung J, Kim SH, Effect of platinum-based chemotherapy on PD-L1 expression on tumor cells in non-small cell lung cancer. Cancer Res Treat 2019;51:1086–1097.30428640)| false
• Search Google Scholar
• Export Citation

Galsky MD, Wang H, Hahn NM, et al. Phase 2 trial of gemcitabine, cisplatin, plus ipilimumab in patients with metastatic urothelial cancer and impact of DNA damage response gene mutations on outcomes. Eur Urol 2018;73:751–759.

• PubMed
Galsky MD, Wang H, Hahn NM, Phase 2 trial of gemcitabine, cisplatin, plus ipilimumab in patients with metastatic urothelial cancer and impact of DNA damage response gene mutations on outcomes. Eur Urol 2018;73:751–759.29248319)| false
• Search Google Scholar
• Export Citation

Kim WS, Kim H, Kwon KW, et al. Cisplatin induces tolerogenic dendritic cells in response to TRL agonists via the abundant production of IL-10, thereby promoting TH2- and Tr1-biased T-cell immunity. Oncotarget 2016;7:33765–33782.

• PubMed
Kim WS, Kim H, Kwon KW, Cisplatin induces tolerogenic dendritic cells in response to TRL agonists via the abundant production of IL-10, thereby promoting TH2- and Tr1-biased T-cell immunity. Oncotarget 2016;7:33765–33782.)| false
• Search Google Scholar
• Export Citation

Hoimes CJ, Albany C, Hoffman-Censits J, et al. Neoadjuvant pembrolizumab plus cisplatin and gemcitabine shows promise in locally advanced urothelial cancer [abstract]. Presented at the ESMO Congress 2018; October 19–23, 2018; Munich, Germany. Abstract LBA 33.

• PubMed
Hoimes CJ, Albany C, Hoffman-Censits J, Neoadjuvant pembrolizumab plus cisplatin and gemcitabine shows promise in locally advanced urothelial cancer [abstract]. Presented at the ESMO Congress 2018; October 19–23, 2018; Munich, Germany. Abstract LBA 33.)| false
• Search Google Scholar
• Export Citation

Grande E, Galsky MD, Arranz Arija JA, et al. IMvigor130: a phase III study of atezolizumab with or without platinum-based chemotherapy in previously untreated metastatic urothelial carcinoma [abstract]. Presented at the ESMO Congress 2019; September 27–October 1, 2019; Barcelona, Spain. Abstract LBA 14.

• PubMed
Grande E, Galsky MD, Arranz Arija JA, IMvigor130: a phase III study of atezolizumab with or without platinum-based chemotherapy in previously untreated metastatic urothelial carcinoma [abstract]. Presented at the ESMO Congress 2019; September 27–October 1, 2019; Barcelona, Spain. Abstract LBA 14.)| false
• Search Google Scholar
• Export Citation

Hoimes CJ, Rosenberg JE, Srinivas S, et al. EV-103: initial results of enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma [abstract]. Presented at the ESMO Congress 2019; September 27–October 1, 2019; Barcelona, Spain. Abstract 4844.

• PubMed
Hoimes CJ, Rosenberg JE, Srinivas S, EV-103: initial results of enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma [abstract]. Presented at the ESMO Congress 2019; September 27–October 1, 2019; Barcelona, Spain. Abstract 4844.)| false
• Search Google Scholar
• Export Citation

Powles T, Park SH, Voog E, et al. Maintenance avelumab + best supportive care (BSC) versus BSC alone after platinum-based first-line (1L) chemotherapy in advanced urothelial carcinoma (UC): JAVELIN Bladder 100 phase III interim analysis [abstract]. Presented at the ASCO20 Virtual Scientific Program; May 29–31, 2020. Abstract LBA1.

• PubMed
Powles T, Park SH, Voog E, Maintenance avelumab + best supportive care (BSC) versus BSC alone after platinum-based first-line (1L) chemotherapy in advanced urothelial carcinoma (UC): JAVELIN Bladder 100 phase III interim analysis [abstract]. Presented at the ASCO20 Virtual Scientific Program; May 29–31, 2020. Abstract LBA1.)| false
• Search Google Scholar
• Export Citation

Flaig TW, Spiess PE, Agarwal N, et al. NCCN Clinical Practice Guidelines in Oncology: Bladder Cancer. Version 2.2021. Accessed March 27, 2021. Available at NCCN.org

• PubMed
Flaig TW, Spiess PE, Agarwal N, NCCN Clinical Practice Guidelines in Oncology: Bladder Cancer. Version 2.2021. Accessed March 27, 2021. Available at NCCN.org)| false
• Export Citation

Powles T, van der Heijden MS, Castellano D, et al. Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial. Lancet 2020;21:1574–1588.

• PubMed
Powles T, van der Heijden MS, Castellano D, Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial. Lancet 2020;21:1574–1588.32971005)| false
• Search Google Scholar
• Export Citation

Bajorin DF, Witjes JA, Gschwend J, et al. First results from the phase 3 CheckMate 274 trial of adjuvant nivolumab vs placebo in patients who underwent radical surgery for high-risk muscle-invasive urothelial carcinoma [abstract]. Presented at the ASCO 2021 Genitourinary Cancers Symposium; February 11–13, 2021. Abstract 391.

• PubMed
Bajorin DF, Witjes JA, Gschwend J, First results from the phase 3 CheckMate 274 trial of adjuvant nivolumab vs placebo in patients who underwent radical surgery for high-risk muscle-invasive urothelial carcinoma [abstract]. Presented at the ASCO 2021 Genitourinary Cancers Symposium; February 11–13, 2021. Abstract 391.)| false
• Export Citation

Balar AV, Kamat AM, Kulkarni GS, et al. Pembrolizumab for the treatment of patients with Bacillus Calmette-Guérin unresponsive, high-risk non–muscle-invasive bladder cancer: over two years follow-up of KEYNOTE-057 [abstract]. Presented at the ASCO20 Virtual Scientific Program; May 29–31, 2020. Abstract 5041.

• PubMed
Balar AV, Kamat AM, Kulkarni GS, Pembrolizumab for the treatment of patients with Bacillus Calmette-Guérin unresponsive, high-risk non–muscle-invasive bladder cancer: over two years follow-up of KEYNOTE-057 [abstract]. Presented at the ASCO20 Virtual Scientific Program; May 29–31, 2020. Abstract 5041.)| false
• Search Google Scholar
• Export Citation